STOCKHOLM -- The sodium glucose co-transporter 2 (SGLT2) class of diabetes medications may offer more protection against diabetic retinopathy as compared with other hypoglycemic agents, an analysis of ...

SGLT2 inhibitor use was associated with a significantly lower risk for androgen deprivation therapy (ADT) failure and next-generation hormonal agent failure in men with prostate cancer. SGLT2 ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk for dementia and Parkinson’s disease, a new study finds. The report was ...

GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type 1 diabetes in recent years, a nationwide cross-sectional analysis found. From 2010 to 2023, the percentage ...

Two classes of diabetes drugs may also improve cardiovascular and kidney disease outcomes in people with or without diabetes. In a meta-analysis involving more than 70,000 patients with diabetes, ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors — a class of drugs used to treat type 2 diabetes — could also prevent dementia, according to a study published Wednesday in The BMJ. The authors ...

A study led by the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine of the University of Hong ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults with type 2 diabetes did not have higher risk for ...

Recent developments of interest in cardiovascular medicine ...

Please provide your email address to receive an email when new articles are posted on . The effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart ...